Strs Ohio Cuts Holdings in Medtronic PLC $MDT

Key Points

• Strs Ohio reduced its Medtronic stake by 6.0%, selling 34,705 shares and ending the quarter with 544,605 shares valued at about $52.3 million.
• EVP Harry Skip Kiil sold 52,524 shares on Feb. 19 for roughly $5.13 million, a 61.6% cut to his ownership; insiders now hold just 0.26% of the stock.
• Analysts are mixed but the consensus is a Moderate Buy with an average price target of $107.80; shares trade near recent lows (~$80), the stock yields 3.5% and Medtronic set FY2026 EPS guidance of $5.62–$5.66.

Strs Ohio decreased its position in Medtronic PLC (NYSE:MDT - Free Report) by 6.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 544,605 shares of the medical technology company's stock after selling 34,705 shares during the period. Strs Ohio's holdings in Medtronic were worth $52,315,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Curbstone Financial Management Corp increased its holdings in Medtronic by 1.8% in the fourth quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company's stock valued at $537,000 after buying an additional 100 shares in the last quarter. New England Capital Financial Advisors LLC increased its holdings in Medtronic by 7.8% in the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company's stock valued at $135,000 after buying an additional 101 shares in the last quarter. Baker Tilly Wealth Management LLC increased its holdings in Medtronic by 3.3% in the fourth quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company's stock valued at $309,000 after buying an additional 102 shares in the last quarter. Riverbend Wealth Management LLC increased its holdings in Medtronic by 3.2% in the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company's stock valued at $332,000 after buying an additional 107 shares in the last quarter. Finally, Maseco LLP increased its holdings in Medtronic by 32.1% in the fourth quarter. Maseco LLP now owns 444 shares of the medical technology company's stock valued at $43,000 after buying an additional 108 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Argus cut their price objective on shares of Medtronic from $125.00 to $115.00 and set a "buy" rating for the company in a report on Monday, April 6th. Robert W. Baird lifted their target price on shares of Medtronic from $92.00 to $93.00 and gave the company a "neutral" rating in a research report on Wednesday, April 15th. Wall Street Zen lowered shares of Medtronic from a "buy" rating to a "hold" rating in a research report on Saturday, April 11th. Wells Fargo & Company assumed coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an "overweight" rating and a $114.00 target price on the stock. Finally, UBS Group dropped their target price on shares of Medtronic from $104.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 22nd. Fifteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $107.80.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.26% of the company's stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for the Stealth AXiS™ surgical system (spine & cranial); management frames the system as an integrated next‑generation navigation, planning and robotics platform that should help drive surgical growth and address hospital demand for consolidated systems. Medtronic plc (MDT) Receives the CE Mark for the Stealth AXiS™ Surgical System
• Positive Sentiment: CE mark in Europe for Stealth AXiS expands Medtronic’s addressable surgical market after earlier U.S. clearance — this supports the company’s surgical robotics/navigation growth story and creates new revenue opportunities in European hospitals. Medtronic’s Stealth AXiS Europe Approval Expands Surgical Growth Story
• Positive Sentiment: Progress on cardiac rhythm devices: Affera’s Sphere‑9 FDA Breakthrough designation and related CE activity for ablation catheters highlight Medtronic’s expanding pulsed‑field and RF ablation portfolio — could boost future electrophysiology revenue if trials and approvals continue to progress. Affera Breakthrough: FDA Nod For Sphere-9 Could Be A Game Changer For Medtronic (MDT)
• Positive Sentiment: FDA cleared a next‑generation mitral valve, and Medtronic has enrolled the first patient in a post‑approval study for the Altaviva tibial neuromodulation system — both items support incremental product revenue and clinical validation across cardiovascular and neuromodulation franchises. Medtronic wins FDA nod for next-gen mitral valve Medtronic enrolls first patient in post-approval study of Altaviva tibial neuromod
• Neutral Sentiment: Industry reports highlight wearable medical device market growth (Australia, Saudi Arabia) that could support long‑term opportunities for Medtronic’s wearable/remote monitoring initiatives, but these are broad market trends rather than company‑specific catalysts. Australia Wearable Medical Devices Market Trends and Forecasts Saudi Arabia Wearable Medical Devices Market Trends and Forecasts
• Neutral Sentiment: Competitor and sector moves — Masimo published a large real‑world study on pulse oximetry accuracy across skin tones; Teleflex named a new CEO; Orchestra BioMed received another FDA Breakthrough designation. These items influence competitive and regulatory context but are not direct Medtronic earnings drivers. Masimo SET Shows Accurate Pulse Oximetry in Newborns of All Skin Tones Teleflex Appoints Jason Weidman as President and CEO FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
• Negative Sentiment: Technical/market weakness: coverage noting MDT trading near multi‑month/1‑year lows highlights investor concern about valuation and near‑term momentum despite the product wins — this likely contributes to downward pressure on the stock. Medtronic Near Lows: S&P 500 Index Healthcare Story to Watch

Medtronic Stock Down 1.2%

Shares of NYSE MDT opened at $80.02 on Friday. The company's 50-day simple moving average is $88.44 and its 200-day simple moving average is $94.82. Medtronic PLC has a 52-week low of $78.91 and a 52-week high of $106.33. The firm has a market cap of $102.74 billion, a price-to-earnings ratio of 22.29, a price-to-earnings-growth ratio of 2.10 and a beta of 0.62. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were given a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.5%. Medtronic's payout ratio is presently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.